BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 27494557)

  • 1. Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
    Tycko J; Myer VE; Hsu PD
    Mol Cell; 2016 Aug; 63(3):355-70. PubMed ID: 27494557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [CRISPR/CAS9, the King of Genome Editing Tools].
    Bannikov AV; Lavrov AV
    Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes.
    Jacobi AM; Rettig GR; Turk R; Collingwood MA; Zeiner SA; Quadros RM; Harms DW; Bonthuis PJ; Gregg C; Ohtsuka M; Gurumurthy CB; Behlke MA
    Methods; 2017 May; 121-122():16-28. PubMed ID: 28351759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision genome editing using CRISPR-Cas9 and linear repair templates in C. elegans.
    Paix A; Folkmann A; Seydoux G
    Methods; 2017 May; 121-122():86-93. PubMed ID: 28392263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering the Delivery System for CRISPR-Based Genome Editing.
    Glass Z; Lee M; Li Y; Xu Q
    Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome editing via delivery of Cas9 ribonucleoprotein.
    DeWitt MA; Corn JE; Carroll D
    Methods; 2017 May; 121-122():9-15. PubMed ID: 28410976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional Control of CRISPR/Cas9 Function.
    Zhou W; Deiters A
    Angew Chem Int Ed Engl; 2016 Apr; 55(18):5394-9. PubMed ID: 26996256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila.
    Gratz SJ; Ukken FP; Rubinstein CD; Thiede G; Donohue LK; Cummings AM; O'Connor-Giles KM
    Genetics; 2014 Apr; 196(4):961-71. PubMed ID: 24478335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 in Genome Editing and Beyond.
    Wang H; La Russa M; Qi LS
    Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplexed conditional genome editing with Cas12a in
    Port F; Starostecka M; Boutros M
    Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22890-22899. PubMed ID: 32843348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome editing using CRISPR/Cas9-based knock-in approaches in zebrafish.
    Albadri S; Del Bene F; Revenu C
    Methods; 2017 May; 121-122():77-85. PubMed ID: 28300641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis for Guide RNA Processing and Seed-Dependent DNA Targeting by CRISPR-Cas12a.
    Swarts DC; van der Oost J; Jinek M
    Mol Cell; 2017 Apr; 66(2):221-233.e4. PubMed ID: 28431230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision genome editing in the CRISPR era.
    Salsman J; Dellaire G
    Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene editing in mouse zygotes using the CRISPR/Cas9 system.
    Wefers B; Bashir S; Rossius J; Wurst W; Kühn R
    Methods; 2017 May; 121-122():55-67. PubMed ID: 28263886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs.
    Fu Y; Sander JD; Reyon D; Cascio VM; Joung JK
    Nat Biotechnol; 2014 Mar; 32(3):279-284. PubMed ID: 24463574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.
    Berkhout B; Gao Z; Herrera-Carrillo E
    Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving CRISPR-Cas9 On-Target Specificity.
    Jamal M; Ullah A; Ahsan M; Tyagi R; Habib Z; Rehman K
    Curr Issues Mol Biol; 2018; 26():65-80. PubMed ID: 28879857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
    Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
    Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.